IGHE and anaphylaxis: In order to determine whether this difference was simply a dose issue, we tested the single hSAgAp79 at 5 nmol (a dose equal to both peptides of hSAgAmix combined) and we observed that these mice had an incidence of anaphylaxis comparable to hSAgAmix-treated mice (Figure 4B), as well as comparable levels of total IgG1 (Figure 4C), IgE (Figure 4D), and anti-p79 IgG1 (Figure 4E) after 6 weekly doses.